Antengene Corporation Ltd. has announced a new global clinical collaboration with MSD to evaluate the combination of ATG-022, a CLDN18.2-targeting antibody-drug conjugate, and KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy, in patients with advanced solid tumors. This collaboration aims to explore the efficacy of ATG-022, which has demonstrated significant activity across varying levels of Claudin 18.2 expression in gastric cancer, positioning it as a potential treatment option for a broad patient demographic. The announcement was made on May 20, 2025, highlighting Antengene's commitment to developing innovative cancer therapies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。